Clinical Trials
16 trialsNCT04458259 2026-06-04
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
Pfizer
Phase 1 Terminated
NCT05861947 2026-04-17
JIVAN
Aurigene Discovery Technologies Limited
Phase 1 Terminated
NCT05489250 2026-02-05
PLATON
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Terminated
NCT06682806 2026-02-02
A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Prelude Therapeutics
Phase 2 Terminated
NCT05070247 2026-01-22
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
Phase 1/2 Terminated
NCT05977322 2025-12-24
A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors.
Novartis
Phase 1 Terminated
NCT03676478 2025-12-10
EFECTS
University Hospital, Gasthuisberg
Phase NA Terminated
NCT05169437 2025-10-29
PAVO
Tempus AI
Phase 2 Terminated
NCT03144661 2025-10-21
An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies
Incyte Corporation
Phase 1 Terminated
NCT06336148 2025-10-15
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
Actym Therapeutics, Inc.
Phase 1 Terminated
NCT04938973 2025-09-17
RAMIE vs OTE
St. Joseph's Healthcare Hamilton
Phase NA Terminated
NCT05714553 2025-07-18
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
NuCana plc
Phase 1/2 Terminated
NCT04116320 2025-07-14
AM-003
University of Virginia
Phase 1 Terminated
NCT05563272 2025-07-10
STARBURST
Telix Pharmaceuticals (Innovations) Pty Limited
Phase 2 Terminated
NCT03153280 2025-07-08
Lithium
Cancer Trials Ireland
Phase 1 Terminated
NCT05432193 2025-06-25
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
Eli Lilly and Company
Phase 1 Terminated